Home > Healthcare > Pharmaceuticals > Finished Drug Form > Non-opioid Pain Treatment Market

Non-opioid Pain Treatment Market Share

Report ID: GMI11178
Published Date: Sep 2024
Report Format: PDF

Download Free Sample

Non-opioid Pain Treatment Market Share

The market is characterized by intense competition among various pharmaceutical companies, driven by the growing demand for safer, non-addictive pain management solutions. Companies focus on expanding their product portfolios with innovative formulations, including extended-release and combination therapies. Research and development are key, with many companies investing in advanced drug delivery systems and novel compounds. Additionally, market players compete through strategic collaborations, acquisitions, and geographic expansion to strengthen their presence in this rapidly evolving market.

Non-opioid Pain Treatment Market Companies

Few of the prominent players operating in the non-opioid pain treatment industry include:

Amgen Inc.
Almatica Pharma LLC
Eli Lilly and Company
Fresenius Kabi AG
GlaxoSmithKline plc
Haleon group
Heron Therapeutics
Hyloris Pharmaceuticals
Johnson & Johnson Consumer Inc.
Neumentum Inc.
Novartis AG
Par Pharmaceutical, Inc.
Pfizer Inc.
Sanofi
Scilex Holding Company
Sun Pharmaceutical Industries Ltd.
Vertex Pharmaceuticals
WEX Pharmaceuticals Inc.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global non-opioid pain treatment industry was valued at USD 47.2 billion in 2023 and is anticipated to register 7.3% CAGR between 2024 and 2032 due to the growing advancements in the drug delivery system.

The hospital pharmacies segment in the market accounted for USD 21.1 billion in 2023 due to their extensive accessibility, convenience, and ability to offer a broad range of pain treatments and patient counseling.

U.S. non-opioid pain treatment market accounted for USD 19.2 billion in 2023 due to its advanced healthcare infrastructure and significant investment in research and development.

Amgen Inc., Almatica Pharma LLC, Eli Lilly and Company, Fresenius Kabi AG, GlaxoSmithKline plc, Haleon group, Heron Therapeutics, Hyloris Pharmaceuticals, and Johnson & Johnson Consumer Inc., among others.